Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adaptimmune Therapeutics plc (ADAP)

8   0.02 (0.25%) 10-01 09:34
Open: 7.63 Pre. Close: 7.98
High: 8 Low: 8
Volume: 2,091 Market Cap: 1,237M
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 430 full-time employees. The firm is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The firm has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The firm engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The firm is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. The company has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.322 - 8.368 8.368 - 8.411
Low: 7.465 - 7.522 7.522 - 7.574
Close: 7.894 - 7.98 7.98 - 8.059

Technical analysis

as of: 2020-09-30 4:38:16 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 11.18     One year: 12.77
Support: Support1: 7.37    Support2: 6.13
Resistance: Resistance1: 9.57    Resistance2: 10.93
Pivot: 8.84
Moving Average: MA(5): 7.82     MA(20): 8.63
MA(100): 8.66     MA(250): 4.90
MACD: MACD(12,26): -0.18     Signal(9):
Stochastic oscillator: %K(14,3): 12.83     %D(3): 12.42
RSI: RSI(14): 43.89
52-week: High: 13.40  Low: 0.71  Change(%): 523.4
Average Vol(K): 3-Month: 74664  10-Days: 60180

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
ADAP has closed above bottom band by 31.2%. Bollinger Bands are 36.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 30 Sep 2020
Is Adaptimmune Therapeutics PLC - ADR (ADAP) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Tue, 29 Sep 2020
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Sees Large Increase in Short Interest - MarketBeat

Mon, 28 Sep 2020
Adaptimmune Therapeutics plc (ADAP) Bears Seem To Be Pulling The Price Back - Invest Million

Sat, 26 Sep 2020
Adaptimmune Therapeutics plc (NASDAQ:ADAP) surprises Wall Street with 1.55% stock price gain - Marketing Sentinel

Thu, 24 Sep 2020
Should You Buy Adaptimmune Therapeutics PLC - ADR (ADAP) Stock on Thursday? - InvestorsObserver

Mon, 21 Sep 2020
Bearish Stock to Watch: Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) - FXDailyReport.com

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 155
Shares Float (M) 69
% Held by Insiders 0.20
% Held by Institutions 50.74
Shares Short (K) 3,250
Shares Short P. Month (K) 3,890

Stock Financials

EPS -1.080
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.640
Profit Margin
Operating Margin -5856.96
Return on Assets (ttm) -21.7
Return on Equity (ttm) -42.6
Qtrly Rev. Growth 219.7
Gross Profit (p.s.) -0.623
Sales Per Share 0.014
EBITDA (p.s.) -0.792
Qtrly Earnings Growth
Operating Cash Flow (M) -50
Levered Free Cash Flow (M) -54

Stock Valuations

PE Ratio -7.39
PEG Ratio
Price to Book value 3.02
Price to Sales 553.27
Price to Cash Flow -24.58

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date 2018-03-29
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.